ZNF133 is a Potent Suppressor in Breast Carcinogenesis Through Dampening L1CAM, a Driver for Tumor Progression

Lifang Li,Xuefei Wang,Kai Hu,Xinhua Liu,Li Qiu,Changsen Bai,Yanfen Cui,Biyun Wang,Zhaosong Wang,Hailong Wang,Runfen Cheng,Jialei Hua,Linyue Hai,Mengdie Wang,Miao Liu,Zian Song,Chunhua Xiao,Binghui Li
DOI: https://doi.org/10.1038/s41388-023-02731-5
IF: 8.756
2023-01-01
Oncogene
Abstract:Due to the complexity and heterogeneity of breast cancer, the therapeutic effects of breast cancer treatment vary between subtypes. Breast cancer subtypes are classified based on the presence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2. Thus, novel, comprehensive, and precise molecular indicators in breast carcinogenesis are urgently needed. Here, we report that ZNF133, a zinc-finger protein, is negatively associated with poor survival and advanced pathological staging of breast carcinomas. Moreover, ZNF133 is a transcription repressor physically associated with the KAP1 complex. It transcriptionally represses a cohort of genes, including L1CAM, that are critically involved in cell proliferation and motility. We also demonstrate that the ZNF133/KAP1 complex inhibits the proliferation and invasion of breast cancer cells in vitro and suppresses breast cancer growth and metastasis in vivo by dampening the transcription of L1CAM. Taken together, the findings of our study confirm the value of ZNF133 and L1CAM levels in the diagnosis and prognosis of breast cancer, contribute to a deeper understanding of the regulation mechanism of ZNF133 for the first time, and provide a new therapeutic strategy and precise intervention target for breast cancer.
What problem does this paper attempt to address?